Transanal Irrigation for LARS
(TAI-LARS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate how Transanal Irrigation (TAI), a daily procedure for aiding bowel movements, can enhance life for individuals who have undergone rectal cancer surgery and experience LARS (bowel issues post-surgery). Participants will learn TAI through an online platform with virtual nursing support to assess its effectiveness in North America. The trial includes two groups: one using TAI and the other continuing their usual care. Suitable candidates have had rectal cancer surgery, completed treatment over six months ago, and experience significant daily bowel problems. As an unphased trial, this study offers participants the opportunity to explore a potentially life-improving method with personalized support.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that Transanal Irrigation is safe for patients with LARS?
Studies have shown that transanal irrigation (TAI) can help people with low anterior resection syndrome (LARS) by reducing symptoms and improving quality of life. Research indicates that TAI works well over the long term, with patients experiencing significant relief and high satisfaction even after five years.
TAI is generally easy to tolerate, with many patients using it without major problems. While some studies highlight its benefits, others suggest the evidence isn't entirely convincing. This indicates that while TAI looks promising, more research is needed to confirm its true effectiveness.
Overall, TAI seems to offer benefits with manageable safety. However, like any treatment, individual reactions may vary, so discussing personal health needs with a doctor is important.12345Why are researchers excited about this trial?
Researchers are excited about transanal irrigation (TAI) for managing Low Anterior Resection Syndrome (LARS) because it offers a new approach compared to standard treatments like dietary modifications and medications. TAI is unique in that it directly cleanses the bowel using water, which can provide more immediate relief from symptoms like fecal incontinence and constipation. This method empowers patients to have more control over their bowel management, potentially improving their quality of life significantly and reducing reliance on medications.
What evidence suggests that Transanal Irrigation is effective for LARS?
This trial will compare the effectiveness of transanal irrigation (TAI) with traditional care for managing low anterior resection syndrome (LARS). Research has shown that TAI can greatly help people with LARS. Studies have found that patients using TAI have better control over gas and bowel movements compared to those who don't use it. Another study found that TAI lowered LARS scores, effectively reducing symptoms. Patients reported feeling more satisfied and experiencing a better quality of life with TAI as a long-term treatment. These findings suggest that TAI is a promising option for managing LARS symptoms.5678
Are You a Good Fit for This Trial?
This trial is for Canadian rectal cancer survivors who have completed treatment at least 6 months ago, including ileostomy closure if applicable. They should be experiencing low anterior resection symptoms (LARS) with a score over 20 points and must be able to give informed consent in English or French and access the internet.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants in the intervention arm perform Transanal Irrigation (TAI) every 1-2 days for six months, with virtual nursing support and educational materials provided through the eLARS platform.
Control
Participants in the control arm continue with traditional care, including dietary modifications and medications, without changes to their current management routine.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments of quality of life and bowel function.
What Are the Treatments Tested in This Trial?
Interventions
- Transanal Irrigation
Transanal Irrigation is already approved in European Union, Canada for the following indications:
- Low Anterior Resection Syndrome (LARS)
- Low Anterior Resection Syndrome (LARS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jewish General Hospital
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator
CHU de Quebec-Universite Laval
Collaborator